CD19 and B-cell non-Hodgkin lymphoma: In murine models of human B-cell lymphoma, oncolytic adenovirus LOAd703-infected lymphoma cells exhibited enhanced immunogenic profiles with upregulated co-stimulatory molecules and chemokines, leading to enhanced CD19-CAR-T cell recruitment and anti-tumor activity (80).